-2.9 | | KPTN | 'P-bodies (cytosolic RNP granules)' vs 'pre-sorted fraction' | fraction | RNA-Seq of purified P-bodies from HEK293 cells |
2.8 | | KPTN | 'sebaceous of Jadassohn nevus' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
-2.8 | | KPTN | 'colorectal carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-2.8 | | KPTN | 'breast carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
2.6 | | KPTN | 'actinic keratosis' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
2.6 | | KPTN | 'squamous cell carcinoma' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
2.4 | | KPTN | 'multiple sclerosis; after IFN-beta treatment' vs 'normal' in 'neutrophils' | cell type, disease, treatment | Next generation sequencing of human immune cell subsets across diseases |
-2.3 | | KPTN | 'replicatively senescent; grown until growth arrest' vs 'spontaneously immortal cells; control' | phenotype, treatment | Pathway Profiling of Replicative and Induced Senescence |
-2.2 | | KPTN | 'pancreatic adenocarcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
2.1 | | KPTN | '24 hour' vs '0 hour' in 'MCF-10A' | cell line, time | Knock-in of PIK3CA-H1047R into MCF-10A |
2 | | KPTN | 'DMSO' in 'stimulated with interferon gamma and lipopolysaccharide' vs 'none' at '24 hour' | compound, time, treatment | GPBAR1 agonism has a broad impact on blocking macrophage activation |
-2 | | KPTN | 'tumor necrosis factor alpha' vs 'none' in 'brain microvascular endothelial cell; co-culture' | cell type, growth condition, stimulus | Reactive astrocytes transduce blood-brain barrier inflammation through a TNFα-STAT3 signaling axis and secretion of alpha 1-antichymotrypsin |
-2 | | KPTN | 'non-small cell lung carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-2 | | KPTN | 'hepatobiliary carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-1.8 | | KPTN | '5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide; 0.4 millimolar' vs 'none' | compound | Transcriptome of primary acute myeloid leukemia (AML) cells treated with AICAr |
-1.8 | | KPTN | 'glioblastoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-1.7 | | KPTN | 'SAP130 knock-down' vs 'mock' | RNA interference | RNA-seq analysis of vorinostat-resistant HCT116 cells following gene knockdown of potential vorinostat-resistance candidate genes |
-1.7 | | KPTN | 'fibroblast; Klinefelter’s Syndrome' vs 'embryonic stem cell; control' | cell type, disease | Expression data of the iPSCs derived from foreskin fibroblast cells of normal person and KS patient |
1.7 | | KPTN | '12 hour' vs '0 hour' in 'MCF-10A-H1047R' | cell line, time | Knock-in of PIK3CA-H1047R into MCF-10A |
1.6 | | KPTN | 'estrogen receptor alpha shRNA' vs 'scrambled shRNA' | RNA interference | RNA-seq of the human breast cancer ERα-suppressed MCF-7(MCF-7/SP10+) cells and of their internal control MCF-7 (MCF-7/C) cells |
1.6 | | KPTN | '24 hour' vs '0 hour' in 'MCF-10A-H1047R' | cell line, time | Knock-in of PIK3CA-H1047R into MCF-10A |
-1.6 | | KPTN | 'aging cells' vs 'spontaneously immortal cells; control' | phenotype, treatment | Pathway Profiling of Replicative and Induced Senescence |
-1.6 | | ENSG00000118162 | 'COVID-19' vs 'normal' in 'colon' | disease, organism part | Lung and colon transcriptome profiling of fatal COVID-19 cases |
1.5 | | KPTN | 'KLF17 overexpression' vs 'wild type' at '5 day' | phenotype, time | RNA-seq of hESCs undergoing primed to naive-like resetting via exogenous KLF17 overexpression |
1.5 | | KPTN | 'differentiated; hAKPC-P' vs 'undifferentiated; hIPod' | cell type, phenotype | Differentiation of human amniotic fluid kidney progenitor cells into podocytes and comparison with human conditionally immortalized podocytes |
1.5 | | KPTN | 'differentiated; hAKPC-P' vs 're-differentiated; hIPod' | cell type, phenotype | Differentiation of human amniotic fluid kidney progenitor cells into podocytes and comparison with human conditionally immortalized podocytes |
-1.5 | | KPTN | 'young cells' vs 'spontaneously immortal cells; control' | phenotype, treatment | Pathway Profiling of Replicative and Induced Senescence |
-1.4 | | KPTN | 'SA181; hepatocyte-like cell' vs 'SA181; embryonic stem cell' | block, cell line, cell type, fraction | Gene expression profile of human embryonic stem cell-derived hepatocyte-like cells |
1.3 | | KPTN | 'doxycycline; 0.5 microgram per milliliter; Day 3 post Neurogenin induction' vs 'control' | compound, treatment | Rapid neurogenesis through transcriptional activation in human stem cell (RNA-Seq) |
1.3 | | KPTN | 'EX00000246; stimulated with interferon gamma and lipopolysaccharide' vs 'none' at '24 hour' | compound, time, treatment | GPBAR1 agonism has a broad impact on blocking macrophage activation |
-1.3 | | KPTN | 'shSUZ12' vs 'control' | RNA interference | RNA-seq transcriptional profiling in primary human erythroid progenitor cells upon shRNA-mediated knockdown of PRC2 core subunits |
1.3 | | KPTN | 'KLF17 overexpression' at '5 day' vs 'wild type' at '0 day' | phenotype, time | RNA-seq of hESCs undergoing primed to naive-like resetting via exogenous KLF17 overexpression |
-1.3 | | KPTN | 'HNF4a homozygous deletion mutant (DBD Mut)' vs 'wild type' | genetic modification | Transcriptomic profiling of mutant and WT HNF4alpha hepatic progenitor stage cells |
-1.3 | | KPTN | 'Influenza A virus (A/California/07-00001/2009(H1N1))' vs 'none' in 'poly(I:C); 25 microgram per milliliter; none' | compound, infect, stimulus | RNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C. |
1.3 | | KPTN | 'multiple sclerosis; after IFN-beta treatment' vs 'normal' in 'whole blood' | cell type, disease, treatment | Next generation sequencing of human immune cell subsets across diseases |
-1.3 | | KPTN | 'deprived of Methionine' vs 'control media' in 'MCF7' at '24 hour' | cell line, growth condition, time | Transcription profiling by array of human MCF-7 and PC3 cells grown under amino acid deprived or rich conditions for 24 or 48 hours |
-1.3 | | KPTN | 'tumor necrosis factor alpha' vs 'none' in 'brain microvascular endothelial cell; monoculture' | cell type, growth condition, stimulus | Reactive astrocytes transduce blood-brain barrier inflammation through a TNFα-STAT3 signaling axis and secretion of alpha 1-antichymotrypsin |
-1.3 | | KPTN | 'brodalumab; 350 milligram' vs 'placebo' in 'lesional' at '15 day' | clinical information, compound, time | Gene expression profiling in psoriatic lesional and non-lesional skin [brodalumab treatment] |
-1.3 | | KPTN | 'kidney transplant; transplant rejection; borderline' vs 'none; normal; none' | clinical information, disease, disease staging | Expression of the IL-17/Th17 axis in the development of acute renal allograft rejection |
-1.3 | | KPTN | 'p53KO; tunicamycin' vs 'p53KO; control' | genotype, treatment | Induction of ER stress in HCT116 colon cancer cells |
-1.2 | | KPTN | 'HNF4a point mutated clone (SUMO Mut)' vs 'wild type' | genetic modification | Transcriptomic profiling of mutant and WT HNF4alpha hepatic progenitor stage cells |
1.2 | | KPTN | 'HL-60(TB); promyelocytic leukemia; P04' vs 'HL-60(TB); promyelocytic leukemia; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
-1.2 | | KPTN | ' neural stem cell' vs 'induced pluripotent stem cell' in 'normal' | cell type, disease | Human iPSC-Derived Cerebellar Neurons from a Patient with Ataxia-Telangiectasia Reveal Disrupted Gene Regulatory Networks |
-1.2 | | KPTN | 'ChiPS4; hepatocyte-like cell' vs 'ChiPS4; induced pluripotent stem cell' | block, cell line, cell type, fraction | Gene expression profile of human embryonic stem cell-derived hepatocyte-like cells |
1.2 | | KPTN | 'Human gammaherpesvirus 4' at '14 day' vs 'none' at '0 day' | infect, time | Infection of naïve primary human B-lymphocytes with Epstein-Barr virus (EBV) – time course transcriptomic analysis in the pre-latent phase of viral infection |
-1.2 | | KPTN | 'Alzheimers disease' vs 'normal' in 'entorhinal cortex' | disease, organism part | Microarray analysis of six brain areas from Alzheimers disease patients and normal individuals |
-1.2 | | KPTN | 'valproic acid; 15 millimolar' vs 'control' at '2 day' | compound, sampling time point | RNA-seq of Primary Human Hepatocytes (PHH) exposed to Valproic Acid (VPA) for 3 days daily and 3 days daily exposure followed by 3 days washout. |
1.2 | | KPTN | 'Human gammaherpesvirus 4' at '5 day' vs 'none' at '0 day' | infect, time | Infection of naïve primary human B-lymphocytes with Epstein-Barr virus (EBV) – time course transcriptomic analysis in the pre-latent phase of viral infection |
1.2 | | KPTN | "after autologous stem cell transplantation" vs "before autologous stem cell transplantation" | time | RNA-seq of human multiple myeloma patients myeloid-derived suppressor cells (M-MDSC) |
1.2 | | KPTN | 'poly(I:C); 25 microgram per milliliter' vs 'none' in 'none; none' | compound, infect, stimulus | RNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C. |
-1.2 | | KPTN | 'transplant rejection; borderline' vs 'normal; none' in 'kidney transplant' | clinical information, disease, disease staging | Expression of the IL-17/Th17 axis in the development of acute renal allograft rejection |
1.1 | | KPTN | 'SPI1 -/-' vs 'SPI1 +/+' | genotype | RNA-seq of RS4:11 cell line populations that are unedited (SPI1 +/+), mono (SPI1 +/-) and biallelicaly edited (SPI1 -/-) |
1.1 | | KPTN | 'cisplatin; 100 micromolar' vs 'none' in 'scrambled siRNA' | RNA interference, compound | RNA-seq of human head and neck cancer cell line SQD9 knock-out for TMEM45A exposed to cisplatin |
1.1 | | KPTN | '5-aza-deoxy-cytidine; 10 micromolar' vs 'none' | compound | Expression data for HT29 cells treated with 5-aza-deoxy-cytidine [RNA-Seq] |
-1.1 | | KPTN | 'ELP3 shRNA' vs 'scrambled shRNA' | RNA interference | BT549 cells depleted of ELP3 compared to control |
1.1 | | KPTN | 'tuberculosis' vs 'normal' | disease | Expression data from peripheral blood |
-1.1 | | KPTN | 'siRNA-SIN3A silenced' vs 'control' | RNA interference | SIN3A-regulated LIF-responsive genes in MCF7 cells |
1.1 | | KPTN | 'HCC-2998; colon carcinoma; P10' vs 'HCC-2998; colon carcinoma; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
1.1 | | KPTN | '6 hour' vs '0 hour' in 'MCF-10A' | cell line, time | Knock-in of PIK3CA-H1047R into MCF-10A |
1.1 | | KPTN | 'differentiated; hAKPC-P' vs 'undifferentiated; hAKPC-P' | cell type, phenotype | Differentiation of human amniotic fluid kidney progenitor cells into podocytes and comparison with human conditionally immortalized podocytes |
-1.1 | | KPTN | 'kidney transplant; transplant rejection; acute' vs 'none; normal; none' | clinical information, disease, disease staging | Expression of the IL-17/Th17 axis in the development of acute renal allograft rejection |
1.1 | | KPTN | 'docosahexaenoic acid; lipopolysaccharide' vs 'docosahexaenoic acid; vehicle' | clinical history, stimulus | Transcription profiling by array of human peripheral blood mononuclear cells from patients with hypertriglyceridemia after treatment with docosahexaenoic acid and/or lipopolysaccharide |
1.1 | | KPTN | '10 micromolar; 5-Aza' vs 'vehicle' | compound | Expression data for HT29 cells treated with 5-aza-deoxy-cytidine [Affymetrix] |
1.1 | | KPTN | 'hyperglycemic condition' vs 'non-diabetic condition' | clinical information | Transcription profiling by array of human pancreatic beta cells transplanted into mice |
1.1 | | KPTN | 'astrocyte overexpressing 7 genes' vs 'glioblastoma cell line' | phenotype | Transcription profiling by array of human primary astrocytes, cancer stem cells derived from astrocytes overexpressing various oncogenic and iPSC-inducing factors, glioma stem cells and gliblastomat cell line to compare their expression profiles and tumor-initiating capabilities |
-1.1 | | KPTN | 'valproic acid; 15 millimolar' vs 'control' at '1 day' | compound, sampling time point | RNA-seq of Primary Human Hepatocytes (PHH) exposed to Valproic Acid (VPA) for 3 days daily and 3 days daily exposure followed by 3 days washout. |
-1.1 | | ENSG00000118162 | 'lipopolysaccharide' vs 'none' in 'normal' | disease, stimulus | A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis [RNA-Seq] |
1.1 | | KPTN | '180 days after left ventricular assist device placement' vs 'control' | treatment | Identification of differentially expressed transcripts and pathways one week and six months following implant of left ventricular devices |
1.1 | | KPTN | 'psoriasis' vs 'normal' in 'Ovation RNA Amplification V2 kit' | disease, protocol | Dominant Th1 and Minimal Th17 Skewing in Discoid Lupus Revealed by Transcriptomic Comparison with Psoriasis |
-1.1 | | KPTN | 'sepsis' vs 'normal' in 'neutrophils' | cell type, disease, treatment | Next generation sequencing of human immune cell subsets across diseases |
1 | | KPTN | 'injected in NSG-HLA-A2/HHD mouse' vs 'none' in 'none' | stimulus, xenograft | RNA-Seq of T cells sorted from human PBMCs, or from T cells stimulated with CD3/CD28 beads for 4 days, or from the spleen of NSG or NSG-HLA-A2/HHD mice, 7 days after transplantation with human PBMCs |
-1 | | KPTN | 'dexamethasone; 1 micromolar' vs 'vehicle' | compound | RNA-seq in GR18 cell line to identify genes regulated by the Glucocorticoid Receptor (24h treatment) |
1 | | KPTN | 'cisplatin; 100 micromolar' vs 'none' in 'TMEM45A knockdown by siRNA' | RNA interference, compound | RNA-seq of human head and neck cancer cell line SQD9 knock-out for TMEM45A exposed to cisplatin |
1 | | KPTN | 'vehicle; lipopolysaccharide' vs 'vehicle; vehicle' | clinical history, stimulus | Transcription profiling by array of human peripheral blood mononuclear cells from patients with hypertriglyceridemia after treatment with docosahexaenoic acid and/or lipopolysaccharide |
-1 | | KPTN | 'CRISPR/Cas9 mediated knockout of CIC' vs 'wild type genotype' in 'none' | compound, genotype, time | RNA-seq of Glioma Neural Stem (GNS) cell line G144 after MEK inhibition in wild type (WT) and CIC (Capicua) depleted cells. |
1 | | KPTN | 'deferoxamine; 100 nanomolar echinomycin' vs 'deferoxamine; none' | growth condition, treatment | Transcription profiling by array of human glioblastoma cells after stimulation with deferoxamine and treatment with polyamide 1, echinomycin, or HIF-1a siRNA |
-1 | | KPTN | 'ejaculatory azoospermia; Johnsen score count 2' vs 'ejaculatory azoospermia; Johnsen score count 5' | disease, histology | Transcription profiling of human testis samples from men with highly defined and homogenous testicular pathologies reveals patterns that correlate with distinct stages of spermatogenesis |
1 | | KPTN | 'UV' vs 'none' in '(no brct expression) GFP control' | phenotype, stimulus | Transcriptional profiling by array of U2OS cells overexpressing the BRCT domain of PARP1 after UV radiation |
1 | | KPTN | 'plasma cell' vs 'memory B cell' | cell type | Transcription profiling by array of human activated B cells, plasmablasts and plasma cells compared to memory B cells |
-1 | | KPTN | 'POLR2D knock-down' vs 'mock' | RNA interference | RNA-seq analysis of vorinostat-resistant HCT116 cells following gene knockdown of potential vorinostat-resistance candidate genes |
1 | | KPTN | 'UV' vs 'none' in 'brct expression' | phenotype, stimulus | Transcriptional profiling by array of U2OS cells overexpressing the BRCT domain of PARP1 after UV radiation |
-1 | | KPTN | 'transplant rejection; acute' vs 'normal; none' in 'kidney transplant' | clinical information, disease, disease staging | Expression of the IL-17/Th17 axis in the development of acute renal allograft rejection |
1 | | KPTN | 'BRD4 inhibitor JQ1' vs 'none' in 'C918' | cell line, compound | Transcription profiling by array of uveal melanoma cell lines with wild type and mutant G-proteins (GNAQ or GNA11) in response to treatment with BRAD4 inhibitor JQ1 |
1 | | KPTN | 'CD3 and CD28' vs 'none' | compound, disease | Transcription profiling by array of human CD3-positive T cells from patients with systemic lupus erythematosus |
1 | | KPTN | 'astrocyte overexpressing 4 genes' vs 'glioblastoma cell line' | phenotype | Transcription profiling by array of human primary astrocytes, cancer stem cells derived from astrocytes overexpressing various oncogenic and iPSC-inducing factors, glioma stem cells and gliblastomat cell line to compare their expression profiles and tumor-initiating capabilities |
1 | | KPTN | 'NLRC4-Macrophage Activation Syndrome; prior to anakinra treatment' vs 'normal' | disease, treatment | An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome |
1 | | KPTN | '6 hour' vs '0 hour' in 'MCF-10A-H1047R' | cell line, time | Knock-in of PIK3CA-H1047R into MCF-10A |
1 | | KPTN | 'Human gammaherpesvirus 4' at '3 day' vs 'none' at '0 day' | infect, time | Infection of naïve primary human B-lymphocytes with Epstein-Barr virus (EBV) – time course transcriptomic analysis in the pre-latent phase of viral infection |
-1 | | KPTN | 'DICERER5/EX5; tunicamycin' vs 'DICERER5/EX5; control' | genotype, treatment | Induction of ER stress in HCT116 colon cancer cells |
1 | | KPTN | 'erythroleukemia; ZRSR2 shRNA' vs 'normal' | disease, genotype | RNA-seq of bone marrow from patients with myelodysplastic syndrome |
-1 | | KPTN | 'myxosarcoma' vs 'normal' | disease | Atrial Myxomas Arise From Multipotent Myxoid Cardiac Stem Cells |
